Displaying drugs 476 - 500 of 12390 in total
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... [L8336,L8339]
On a weight basis, methimazole is 10 times more potent than the other major antithyroid ... hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … [A202049, A202055, L15986]
Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is ... Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced ... [A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions ... of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... [L10598] It is also available in a combination product with [formoterol].[L10619] …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. ... It is a yellow, odorless, non-hygroscopic, crystalline compound. …
Loracarbef
Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Matched Description: … Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin …
Ciclopirox
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. ... Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a …
Dalfampridine
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Matched Description: … Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. …
Matched Categories: … OCT2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index …
Matched Categories: … OCT2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index …
Agalsidase beta
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after ... Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. ... a contamination event in 2009. …
Clavulanic acid
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus. When it is combined with amoxicillin, clavulanic acid is...
Approved
Vet approved
Matched Description: … Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin ... antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of …
Matched Mixtures name: … AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S ... AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S ... AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S …
Matched Mixtures name: … AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S ... AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S ... AMOXICILLINA E ACIDO CLAVULANICO SANDOZ A/S …
Flufenamic acid
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Phosphoric acid
Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
Approved
Matched Description: … Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. ... Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++ …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Poa annua pollen
Poa annua pollen is the pollen of the Poa annua plant. Poa annua pollen is mainly used in allergenic testing.
Approved
Matched Description: … Poa annua pollen is the pollen of the Poa annua plant. …
Iva annua pollen
Iva annua pollen is the pollen of the Iva annua plant. Iva annua pollen is mainly used in allergenic testing.
Approved
Matched Description: … Iva annua pollen is the pollen of the Iva annua plant. …
Anthrax vaccine
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis...
Approved
Matched Description: … of Bacillus anthracis which are grown in a chemically defined protein-free medium. ... [L47526] It is considered one of the most likely agents to be used in a biological attack. ... Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high …
Susoctocog alfa
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of factor ... These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults …
Viper antivenom
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.
Approved
Matched Description: … Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies ... asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of …
Beroctocog alfa
Approved
Investigational
Acetylcysteine
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168]
Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Matched Description: … [L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications ... Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Products: … FLUIMUCIL A 200 ... FLUIMUCIL A 600 ... FLUIMUCIL A-200 GRANULES …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Products: … FLUIMUCIL A 200 ... FLUIMUCIL A 600 ... FLUIMUCIL A-200 GRANULES …
Amylmetacresol
Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections , . Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils .
The acute sore throat (pharyngitis)...
Approved
Matched Description: … Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the ... treatment of sore throat and minor mouth infections [L2570], [L2571]. ... symptoms, and are increasingly important in the management of this condition [A32787]. …
Moroctocog alfa
Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor...
Approved
Matched Description: … Activation of Factor IX leads to a cascade of signals that results in activation of Factor X, which then ... Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations ... results in the conversion of prothrombin to thrombin, and as a result, leads to the conversion of fibrinogen …
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Investigational
Matched Name: … Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) …
Matched Description: … A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed …
Matched Description: … A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed …
Doripenem
Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that...
Approved
Investigational
Matched Description: … in a premature termination of the trial. ... In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin ... ), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting …
Varenicline
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full...
Approved
Investigational
Matched Description: … Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine ... Varenicline is a prescription medication used to treat smoking addiction. ... A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. …
Displaying drugs 476 - 500 of 12390 in total